Impact of obesity-related genes in Spanish population by Fernando Martínez-García et al.
Martínez-García et al. BMC Genetics 2013, 14:111
http://www.biomedcentral.com/1471-2156/14/111RESEARCH ARTICLE Open AccessImpact of obesity-related genes in Spanish
population
Fernando Martínez-García1,2, María L Mansego3,4, Gemma Rojo-Martínez4,5, Griselda De Marco-Solar3,4,
Sonsoles Morcillo4,5, Federico Soriguer4,5, Josep Redón1,2,8*, Monica Pineda Alonso6, Juan C Martín-Escudero6,
Richard S Cooper7 and Felipe J Chaves3,4Abstract
Background: The objective was to investigate the association between BMI and single nucleotide polymorphisms
previously identified of obesity-related genes in two Spanish populations. Forty SNPs in 23 obesity-related genes
were evaluated in a rural population characterized by a high prevalence of obesity (869 subjects, mean age 46 yr,
62% women, 36% obese) and in an urban population (1425 subjects, mean age 54 yr, 50% women, 19% obese).
Genotyping was assessed by using SNPlex and PLINK for the association analysis.
Results: Polymorphisms of the FTO were significantly associated with BMI, in the rural population (beta 0.87,
p-value <0.001). None of the other SNPs showed significant association after Bonferroni correction in the two
populations or in the pooled analysis. A weighted genetic risk score (wGRS) was constructed using the risk alleles
of the Tag-SNPs with a positive Beta parameter in both populations. From the first to the fifth quintile of the score,
the BMI increased 0.45 kg/m2 in Hortega and 2.0 kg/m2 in Pizarra. Overall, the obesity predictive value was low
(less than 1%).
Conclusion: The risk associated with polymorphisms is low and the overall effect on BMI or obesity prediction is
minimal. A weighted genetic risk score based on genes mainly acting through central nervous system mechanisms
was associated with BMI but it yields minimal clinical prediction for the obesity risk in the general population.
Keywords: Obesity, Genetics, FTO gene, Genetic scoreBackground
Obesity is a global pandemic and a major health concern
because of the consequent morbidity and premature
mortality. Changes in lifestyles resulting in energy intake
and expenditure imbalance have led to an increase in
obesity prevalence all over the world. Although this
trend is driven by the “obesogenic” environment, evidence
demonstrated that it is facilitated by genetic susceptibility,
being the heritability in familial and twin studies of around
40-70%, [1,2].
Although many genetic variants have consistently been
associated with obesity, the individual impact on body
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distribution, and reproduction in any mediumstudies (GWAS), several genes have been associated
with obesity, especially the fat mass and obesity associ-
ated gene (FTO). Initially found in a GWAS of type 2
diabetes, FTO has been consistently associated with
obesity and BMI in many studies [3-6]. Moreover, a
published meta-analysis confirmed the association in
32387 individuals of European ancestry from 15 cohorts
[7]. According to this study, the top hit within the intron 1
of FTO gene was the rs1421085 although all the SNPs
in high linkage disequilibrium (LD) with this variant
were also strongly associated with BMI, including the
rs9939609 the most replicated that increase 31% the
risk of obesity [4].
Other candidate genes have also been linked with
obesity with varying degrees of association. The melano-
cortin 4 receptor (MC4R) gene, linked with monogenic
obesity [8], also has a polygenic effect with the minor
allele of the c.307G > A (rs2229616, p.Val103Ile) beingCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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INSIG2, TMEM18, KCTD15, SH2B1, MTCH2, GNPDA2,
BDNF, or CHST8 genes, have also been associated with
obesity. Furthermore, two other loci, one close to the
NEGR1 gene and another near STK33 were also associated
to obesity in some studies and the NEGR1 gene has
been independently associated with obesity in a pediatric
cohort [11].
A genetic risk score constructed with the FTO, MC4R
and six of the newly discovered loci performed poorly
as a predictor of obesity and the explained variance of
BMI was less than 1% [7]. Due to the heterogeneity of
the trait, however, the predictive value may vary with the
characteristics of the population studied. The objective
of the present study was to assess the association between
individual genetic variants and haplotypes of several
obesity-related genes (FTO, MC4R, MTCH2, NEGR1,
SEC16B, INSIG2, TMEM18, KCTD15, SH2B1, FAIM2,
ATXN2L, BDNF, BDNFOS, GNPDA2, ADRB2, PRL, PTER,
ADIPOQ, ETV5, MAF, NPC1, CTNNBL1, and HTR2C)
and BMI in two Spanish populations. We analyzed in-
teractions between the associated genetic variants in
order to identify functional relationships between genes
and metabolic pathways for BMI regulation. The potential
predictive value of a weighted genetic risk score to predict
obesity was also evaluated.
Methods
Two adult general population samples were used in
the present study, one from Pizarra, a village of 6600
inhabitants which is located in the south of Spain, and
the other from an urban area of Valladolid located in
the center of Spain. All the participants provided written
informed consent and the local ethical committees
approved the studies.
The Pizarra study is a population-based survey of
cardiovascular risk factors. The characteristics of this
population have been previously published [12,13].
Briefly, 2090 subjects aged 18-65 years were randomly
selected from the municipal register. For 1119 out of
2090 individuals demographic, anthropometric and
DNA were available. Persons with severe clinical or
psychological problems, pregnant women and those who
were institutionalized were excluded. This population
has a prevalence of obesity higher than that reported
for other Spanish communities. From this population,
we were only able to use 869 subjects for the final analysis
(131 were excluded because of lack of complete informa-
tion and 119 due to that they did not pass the quality
thresholds).
The selection process of the Hortega study has also
been previously published [14,15]. Briefly, subjects older
than 18 years old were randomly selected from the
public register of the western medical area of Valladolid(Spanish National Statistical Institute; http://ine.es). Sub-
jects were invited to participate in the study by phone.
Individuals with serious concomitant diseases or psychi-
atric disorders were excluded. A second list of subjects
was selected to replace those who reclined to take part in
the study. The percentage of replacement was 32%. The
calculated minimal sample size required to be representa-
tive of the population was 1400, and 1504 individuals were
finally recruited. From this population, we were only able
to use 1425 subjects for the final analysis (2 were excluded
because of technical reasons and 77 due to that they did
not pass the quality thresholds).
The names of the institutional boards which approved
the study were: Institutional board of the Clinical Hospital
Río Hortega in Valladolid. Institutional board of the Carlos
Haya Hospital in Malaga.
Anthropometric measurements
The anthropometric parameters were measured for all
the individuals according to standard procedures in the
two studies. Weight was assessed with a precise scale
while the subjects were wearing light clothes and bare-
foot. Height was assessed in a similar way. Body mass
index (BMI) was calculated as weight divided by height2
expressed in kg/m2. Obesity was defined as a BMI ≥
30 kg/m2 and overweight as a BMI of 25.0–29.9 kg/m2
[16]. Blood pressure was assessed with an automatic
device following the recommendations of the European
Society of Hypertension. Fasting blood samples for blood
count and serum biochemistry were analyzed by an
auto-analyzer.
Type 2 diabetes definition
In Hortega subjects were considered as diabetics if they
were already diagnosed of type 2 diabetes by a physician
or if the plasma glucose remained equal or higher than
126 mg/dl after the extraction of a second sample in
fasting conditions in those subjects with glucose equal
or higher than 140 mg/dl in non fasting conditions [17].
In Pizarra, the WHO 1998 criteria were used to classify
the people with diabetes, IGT and IFG [12,18]. People
were also considered to have diabetes if they were already
receiving treatment with oral anti-diabetics. Those people
being treated with diet only received an OGTT to verify
the diagnosis.
Genotyping
Blood for the genotyping was taken into tubes with
15% of ethylenediaminetetraacetic acid (EDTA) and
was kept at 4ºC to process in 5 days. Those samples
which were not processed in five days after the extraction
were frozen at -80ºC. DNA was isolated from peripheral
blood cells using Realpure Genomic DNA extraction kit
(Real Pure, Paterna, Spain) and the samples were diluted
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based on a search in the PubMed database of previous
reports about association with obesity in GWAS studies
between the years 2007-2009. Selected SNPs were ge-
notyped using an oligo-ligation assay (SNPlex; Applied
Biosystems, Foster City, CA) following the manufacturer’s
instructions. The characteristics of the selected SNPs and
related genes are shown in Table 1. In both populations
the minor allele frequencies (MAF) were quite similar
to the MAF in the HapMap CEU samples. One SNP,
rs7561317, close to the TMEM18 gene, was excluded
because of being monomorphic.
Statistical analysis
Quantitative variables are expressed as the mean ± stand-
ard deviation (SD). Qualitative variables are expressed as
entire counts or percentage. We used the free software
Quanto v1.2.4 to calculate the statistical power with the
continuous and qualitative traits under an additive genetic
model taking into account the minor allele frequency of
the selected SNPs, the sample size, the mean and standard
deviation of BMI in our sample and the magnitude of the
association for that variants in the literature with a type I
error of 0.05.
To assess the association between genotypes/haplotypes
and BMI, we used linear regression models adjusted by
age and gender under the additive inheritance genetic
model. Because of the relationship of BMI with type 2
diabetes, we also performed the analysis including type
2 diabetes as co-variable. The interaction between
genetic variants and BMI was made by adding a multi-
plicative term within the linear regression model. The
Bonferroni correction adjusted for 26 independent tests
(see Additional file 1: Figure S1 about the LD patterns)
was used to correct for multiple comparisons, being
the corrected p-value for significance of 0.00192.
The r2 was used to measure the linkage disequilibrium
(LD). Haplotype frequencies were estimated by the
Expectation Maximization Algorithm (EM). Tag-SNPs,
LD and haploblocks were calculated using Haploview
version 3.32. The individual SNP and haplotype analysis
was performed with the program PLINK v.1.06 developed
by Purcell (http://pngu.mgh.harvard.edu/purcell/plink/).
The average genotyping call rate to filter individuals
and SNPs was 95%. We also filter those SNPs with a
MAF lower than 1% and with a HWE p-value lower
than 0.001. A weighted genetic risk score (wGRS) was
constructed using the risk alleles of the Tag-SNPs
which showed a positive Beta parameter in Hortega,
Pizarra and the pooled analysis. For each individual, the
number of risk alleles (0,1,2) per SNP was weighted for
their effect sizes and re-scaled by dividing by the average
of the all the effect sizes. The weighted risk alleles for the
selected SNPs were summed for each individual, andthe overall individual sum was rounded to the nearest
integer to represent the individual’s risk allele score.
The comparison of BMI among the quintiles of the
score adjusted for age and sex and the 95% confidence
interval for the means were calculated from the linear
regression estimates. We used the area under the curve
(AUC) from the receiver operating characteristic (ROC)
curves to assess the capability of the score to predict
obesity in the two populations. These procedures were
performed with StataIC 11 (StataCorp4905 Lakeway drive,
College Station, Texas, 77845, USA).
Finally, the statistical heterogeneity of the results for
the two populations was analysed using the p-value for
Cochrane’s Q statistic and the I2 heterogeneity index.
This meta-analysis was also performed with PLINK con-
sidering both fixed and random effect models. Two
SNPs, rs4712652 and rs1424233, were excluded from the
meta-analysis because allele mismatch.Results
The general characteristics of the individuals from the two
populations after removal of subjects with low genotyping
call rate are shown in Table 2. Subjects from Pizarra
population were significantly younger and had higher
BMI and greater prevalence of obesity than those from
the Hortega study. The gender distribution was balanced
in the Hortega population whereas in the Pizarra study
there were more women than men.Association analysis with BMI
Pizarra population: From 988 individuals with complete
information, 119 subjects were excluded because of
low genotyping rate. The genotyping call rate for the
remaining individuals was 99.7 ± 0.9%. Except for the
rs7561317, the rest of SNPs passed the thresholds for
HWE, MAF or call rate. The SNP genotyping call rate
for the remaining SNPs was 99.7 ± 0.45%. The results
of the genetic association study in Pizarra are presented
in Table 3.
All SNPs of the FTO gene within a block of high LD
in intron 1 (r2 > 0.8) were significantly associated with
BMI (beta 0.87, p-value <0.001, for the most associated
SNP, rs9939609). Their impact on BMI, based on the
confident intervals for the beta parameter ranged from
0.31 to 1.34 (average 0.83) as the lowest and highest
limits for the confident intervals (average 1.46). None of
the other variants analysed were significantly associated
with BMI after Bonferroni correction. The only SNPs,
other than FTO which had a p-value lower than 0.05 for
BMI, were the rs17782313 close to the MC4R gene and
the rs10838738 within the MTCH2 gene. When DM2
was included as co-variable the results did not change.
Table 1 Characteristics of the selected SNPs












1p31.1 NEURONAL GROWTH REGULATOR 1 NEGR1 rs3101336 72523773 NT_032977.8:g.42723104C > T 96.80 100 0.237 0.252 0.472/0.663
rs2568958 72537704 NT_032977.8:g.42737035A > G 98.86 100 0.115 0.095 0.858/0.303
rs2815752 72585028 NT_032977.8:g.42784359A > G 98.93 100 0.355 0.349 0.929/0.304
1q25.2 SEC16 HOMOLOG B (S. CEREVISIAE) SEC16B rs10913469 176180142 NM_033127.2:c.1881 + 177A > G 97.80 100 0.154 0.143 0.293/1
2q14.1 INSULIN INDUCED GENE 2 INSIG2 rs7566605 118552495 NT_022135.15:g.7543947C > G 98.20 99.77 0.454 0.439 0.706/0.643
2p25.3 TRANSMEMBRANE PROTEIN 18 TMEM18 rs2867125 612827 NT_022327.14:g.612827T > C 97.47 100 0.351 0.397 0.078/0.186
rs6548238 624905 NT_022327.14:g.624905T > C 98.93 99.88 0.449 0.419 0.043/0.141
rs4854344 628144 NT_022327.14:g.628144G > T 98.73 99.88 0.380 0.387 0.0521/0.164
3q27 ADIPONECTIN, C1Q AND
COLLAGEN DOMAIN
ADIPOQ rs17300539 188042154 NT_005612.15:g.93054610G > A 98.53 99.54 0.433 0.403 0.032/0.342
rs3774261 1 188054253 NM_004797.2:c.215-414A > G 98.20 99.54 0.496 0.484 0.967/0.726
3q28 ETS VARIANT 5 ETV5 rs7647305 187316984 95 98.85 0.118 0.125 0.902/0.655
4p13 GLUCOSAMINE-6-PHOSPHATE
DEAMINASE 2
GNPDA2 rs10938397 44877284 NT_006238.10:g.4884493A > G 97.80 100 0.195 0.198 0.382/0.340
5q31-q32 ADRENERGIC, BETA-2-, RECEPTOR, SURFACE ADRB2 rs12654778 1 148185934 NT_029289.10:g.9368677G > A 98.13 100 0.363 0.330 0.207/0.318
6p22.2-p21.3 PROLACTIN PRL rs4712652 22186594 NT_007592.14:g.12936866G > A 97.07 97.58 0.346 0.375 0.804/0.516
10p12 PHOSPHOTRIESTERASE RELATED PTER rs10508503 16339957 NT_077569.2:g.10662847C > T 96.27 99.19 0.346 0.375 0.006/0.015
11p13 BRAIN-DERIVED NEUROTROPHIC FACTOR BDNF rs4923461 27613486 NR_002832.1:c.244-4482G > A 98.33 99.88 0.169 0.172 0.955/0.637
rs925946 27623778 NR_002832.1:c.404 + 5650G > T 98.47 100 0.347 0.375 0.0001/0.003
rs10501087 27626684 NR_002832.1:c.404 + 8556G > T 98.00 99.65 0.424 0.384 0.779/0.634
rs6265 27636492 NM_001709.3:c.196G > A
(p.V66M)
98.13 100 0.461 0.489 0.373/0.426
11p14.1 BDNF OPPOSITE STRAND
(NON-PROTEIN CODING)
BDNFOS rs4074134 27603861 NR_002832.1:c.244-14107G > C 98.86 99.54 0.185 0.160 0.956/0.841
11p11.2 MITOCHONDRIAL CARRIER HOMOLOG 2 MTCH2 rs4752856 1 47604618 NM_014342.2:c.681 + 590C > T 98.40 99.77 0.240 0.261 0.928/0.699
rs10838738 47619625 NM_014342.2:c.87 + 882T > C 97.87 99.65 0.489 0.455 1/0.545
12q13 FAS APOPTOTIC INHIBITORY MOLECULE 2 FAIM2 rs7138803 48533735 NT_029419.11:g.12390774G > A 98.66 99.42 0.354 0.344 0.391/0.111
16p11 ATAXIN 2-LIKE ATXN2L rs8049439 28745016 NM_007245.2:c.466-46T > C 96.53 100 0.327 0.356 0.619/0.512
16q12.2 FAT MASS AND OBESITY ASSOCIATED FTO rs6499640 52327178 NM_001080432.1:c.45 +
31536A > G
98.07 99.88 0.173 0.173 0.694/0.488
rs1421085 1 52358455 NM_001080432.1:c.46-43098T > C 97.87 100 0.237 0.261 1/0.719
rs1121980 1 52366748 NM_001080432.1:c.46-34805G>A 98.93 100 0.073 0.092 0.617/0.389
rs8050136 1 52373776 NM_001080432.1:c.46-27777C > A 98.86 99.19 0.220 0.228 0.420/0.470




















Table 1 Characteristics of the selected SNPs (Continued)
rs9939609 1 52378028 NM_001080432.1:c.46-23525T > A 98.33 99.88 0.174 0.170 0.966/0.876
rs7190492 52386253 NM_001080432.1:c.46-15300G> A 98.73 99.65 0.351 0.351 0.782/0.438
rs8044769 52396636 NM_001080432.1:c.46-4917C > T 97.33 100 0.339 0.329 0.967/0.880
16q22-q23 V-MAF MUSCULOAPONEUROTIC
FIBROSARCOMA
MAF rs1424233 78240252 99.13 99.77 0.321 0.321 0.805/0.52
16p11.2 SH2B ADAPTOR PROTEIN 1 SH2B1 rs4788102 28780899 NT_010393.15:g.20186477G > A 98.27 99.77 0.224 0.204 0.890/0.466
18q22 MELANOCORTIN 4 RECEPTOR MC4R rs17782313 56002077 NT_025028.13:g.5641943T > C 98.66 100 0.455 0.464 0.215/0.382
18q11-q12 NIEMANN-PICK DISEASE, TYPE C1 NPC1 rs1805081 19394430 NM_000271.3:c.644A > G
(p.H215R)
98.93 99.65 0.343 0.376 0.012/0.017
19q13.11 POTASSIUM CHANNEL TETRAMERISATION KCTD15 rs11084753 39013977 NT_011109.15:g.6590355A > G 97.93 99.65 0.428 0.390 0.184/0.336
20q11.23-q12 CATENIN, BETA LIKE 1 CTNNBL1 rs6013029 35832994 NM_030877.3:c.750 + 3134G > T 98.27 99.88 0.267 0.283 0.574/0.482
Xq24 5-HYDROXYTRYPTAMINE RECEPTOR 2C HTR2C rs3813929 113724776 NT_028405.11:g.250852C > T 98.47 99.88 0.434 0.399 0.168/0.292




















Table 2 Characteristics of the individuals included in the study for Hortega and Pizarra populations after removing
those individuals with low genotyping call rate
Variables HORTEGA study (N = 1425) PIZARRA study (N = 869)
Age (years) 54.4 ± 19.3 46.2 ± 13.8***
Gender, M(%)/F(%) 718 (50.4) / 707 (49.6) 322 (37.2) / 543 (62.8)***
Weight (kg) 70.8 ± 12.9 74.0 ± 14.1***
Height (m) 1.63 ± 0.1 1.6 ± 0.1***
Waist perimeter (cm) (M/F) 95.70 ± 10.15 /83.4 ±12.8 100.6 ± 10.6/ 97.8 ±14.7***
BMI (kg/m2) 26.4 ± 4.2 28.6 ± 5.2***
SBP (mmHg) 130.8 ± 21.5 129.1 ± 21.8
DBP (mmHg) 79.3 ± 10.7 77.7 ± 12.4***
Total Cholesterol (mg/dl) 201.6 ± 38.2 202.6 ± 39.7
LDL Cholesterol (mg/dl)¶ 114.3 ± 34.5 124.2 ± 34.1***
HDL Cholesterol (mg/dl) 51.6 ± 4.2 58.5 ± 13.2***
Triglycerides (mg/dl) 178.1 ± 114.4 99.5 ± 67.0***
Glucose (mg/dl) 92.6 ± 20.7 106.7 ± 30.3***
Obesity (N/%) 253/18. 5 307/36.0 ***
Overweight (N/%) 574/41.9 306/ 35.9*
Abdominal obesity (N/%)+ 388/28.6 514/60.1 ***
DM2 (N/%) 109/7.7 145/18.9 ***
HTN (N/%) 602/42.3 365/42.8
*p-values denote differences between Hortega study and Pizarra study (p < 0.05); <0.01; ***p-values <0.001; M: Male, F: Female, BMI: Body mass index, SBP: Systolic
blood pressure, DBP: Diastolic blood pressure, DM2: Type 2 Diabetes Mellitus, HTN: Hypertension; ¶Calculated with the Friedwald formula; +Abdominal obesity was
defined as waist >102 cm in men and >88 cm in women.
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This study included 1502 subjects but 77 were excluded
because of low genotyping rate (<95%). The average
genotyping call rate after removing them was 99.7 ± 0.7%.
As it was in Pizarra population only the rs7561317
polymorphism had to be excluded. The average SNP
call rate was 99.7 ± 0.5%.
In this population none of the SNPs or haplotypes
reached the significance after Bonferroni correction
(Table 3). The most strongly associated SNPs were on
chromosome 1 near the neuronal growth regulator 1
precursor (NEGR1) gene and are in high LD (beta -0.40,
p-value 0.008 for the association of rs3101336 with
BMI). Other SNPs around nominal p-values for signifi-
cance were rs8049439 located in the ATXN2L gene on
chromosome 16 [beta 0.33 (0.02-0.63), p-value 0.03] and
rs3813929 within the HTR2C gene on chromosome X
[beta -0.43 (-0.88-0.01), p-value 0.05]. The addition of
DM2 did not affect the results of the individual SNPs
analysis.
Pooled analyses
The pooled sample size included 2490 individuals but
196 were excluded because of low genotyping call rate
(<95%). All the SNPs in high LD within the FTO gene
(Additional file 1: Figure S1) were nominally associated
with BMI, Table 3. The allele A of the rs9939609produced an increase of 0.29 in BMI [beta 0.29 (0.03-0.56),
p-value 0.02]. In this case, the most associated SNP was
close to de HTR2C gene on chromosome X. The allele
T of this SNP produced a decrease of about 0.5 in BMI
[beta -0.55 (-0.96 - -0.15), p-value 0.007].
Although a formal test for interaction did not reveal
significant interaction between the SNPs, rs6499640 and
rs1421085 of FTO, however the double homozygotes for
the minor allele had significantly higher BMI values than
double homozygotes for the wild allele (Additional file 2:
Figure S2).
The information about the association of the non-Tag
SNPs with BMI can be consulted in the Additional file 3:
Table S1. Information about the LD and haploblocks can
be consulted in the Additional file 1: Figure S1. The
haplotype association analysis can be consulted in the
Additional file 4: Table S2.Meta-analysis and statistical heterogeneity
For those SNPs in the FTO gene in high LD, the level of
statistical heterogeneity based on the p-value for Cochrane’s
Q statistic and the I2 heterogeneity index, was very high.
For the rest of the SNPs in other loci, the level of
heterogeneity was low or moderate.
None of the SNPs reached the statistical significance
after Bonferroni correction.
Table 3 Individual TagSNP association analysis with BMI adjusted by age and gender under an additive genetic model
in Pizarra, Hortega and the pooled analysis
BMI
Gene SNP A1 MAF Population Prior statistical power N* Beta Standard error STAT** P
FTO rs9939609* A 0.398 PIZARRA 32.77 848 0.875 0.23 3.79 0.0001573
0.435 HORTEGA 66.65 1345 0.1348 0.15 0.90 0.368
0.420 POOLED 77.88 2215 0.2976 0.13 2.19 0.0287
rs8044769 T 0.463 PIZARRA 30.96 848 −0.582 0.23 −2.54 0.0112
0.455 HORTEGA 62.61 1331 −0.1019 0.15 −0.68 0.495
0.458 POOLED 73.98 2198 −0.257 0.13 −1.90 0.0571
rs7190492 A 0.328 PIZARRA 5.06 845 −0.559 0.23 −2.34 0.0192
0.337 HORTEGA 5.16 1346 0.2065 0.16 1.29 0.195
0.333 POOLED 5.21 2213 −0.07336 0.14 −0.51 0.6076
rs6499640 G 0.376 PIZARRA 5.01 847 0.336 0.23 1.43 0.1511
0.381 HORTEGA 5.02 1347 0.09312 0.15 0.60 0.543
0.379 POOLED 5.02 2216 0.2335 0.13 1.69 0.0911
MC4R rs17782313* C 0.199 PIZARRA 9.69 848 0.575 0.28 1.98 0.0478
0.191 HORTEGA 16.33 1348 0.1167 0.19 0.60 0.544
0.195 POOLED 20.23 2218 0.3111 0.17 1.80 0.0716
MTCH2 rs10838738 G 0.352 PIZARRA 5.80 845 0.453 0.24 1.88 0.0603
0.353 HORTEGA 6.98 1348 0.0972 0.15 0.62 0.536
0.353 POOLED 7.61 2215 0.1698 0.14 1.19 0.2318
NEGR1 rs3101336 A 0.375 PIZARRA 7.89 848 −0.084 0.24 −0.34 0.7277
0.343 HORTEGA 11.89 1348 −0.403 0.15 −2.64 0.0083
0.355 POOLED 14.23 2210 −0.1586 0.14 −1.13 0.2561
ATXN2L rs8049439 C 0.375 PIZARRA 8.87 848 −0.139 0.23 −0.58 0.5576
0.338 HORTEGA 14.15 1344 0.3292 0.15 2.13 0.0331
0.353 POOLED 17.35 2209 0.1715 0.14 1.22 0.2198
HTR2C rs3813929 T 0.157 PIZARRA 10.16 847 −0.406 0.35 −1.16 0.2455
0.182 HORTEGA 19.46 1342 −0.4365 0.23 −1.89 0.0577
0.172 POOLED 23.29 2211 −0.5551 0.20 −2.68 0.0073
ADRB2 rs12654778 A 0.388 PIZARRA 3 5.35 848 0.271 0.23 1.16 0.2452
0.380 HORTEGA 69.22 1347 −0.1452 0.15 −0.95 0.339
0.382 POOLED 80.65 2217 0.01463 0.13 0.10 0.9152
SEC16B rs10913469 C 0.142 PIZARRA 9.33 848 0.392 0.32 1.21 0.2266
0.152 HORTEGA 16.43 1347 −0.1609 0.20 −0.78 0.432
0.148 POOLED 19.78 2216 0.00939 0.18 0.05 0.96
TMEM18 rs4854344 G 0.172 PIZARRA 15.26 847 −0.198 0.30 −0.64 0.5173
0.169 HORTEGA 30.08 1348 −0.3012 0.20 −1.48 0.138
0.170 POOLED 37.86 2217 −0.243 0.18 −1.33 0.1815
INSIG2 rs7566605 C 0.327 PIZARRA 13.68 846 0.101 0.24 0.41 0.676
0.321 HORTEGA 26.42 1348 −0.0301 0.16 −0.18 0.8514
0.322 POOLED 33.12 2216 0.1152 0.14 0.79 0.4265
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Table 3 Individual TagSNP association analysis with BMI adjusted by age and gender under an additive genetic model
in Pizarra, Hortega and the pooled analysis (Continued)
ADIPOQ rs17300539 A 0.126 PIZARRA 7.59 844 −0.072 0.33 −0.21 0.8298
0.118 HORTEGA 11.08 1348 0.1146 0.22 0.51 0.6082
0.120 POOLED 13.15 2214 0.0818 0.20 0.40 0.6838
rs3774261 A 0.495 PIZARRA 10.96 844 −0.036 0.22 −0.16 0.8727
0.461 HORTEGA 19.84 1346 −0.0549 0.15 −0.36 0.7138
0.473 POOLED 26.42 2210 0.0609 0.13 0.45 0.6503
ETV5 rs7647305 T 0.205 PIZARRA 10.76 838 0.022 0.28 0.079 0.9364
0.215 HORTEGA 19.82 1325 0.2402 0.18 1.30 0.1927
0.213 POOLED 24.39 2175 0.2106 0.16 1.26 0.2077
GNPDA2 rs10938397 G 0.440 PIZARRA 11.60 848 −0.338 0.22 −1.52 0.1278
0.455 HORTEGA 21.56 1348 −0.048 0.15 −0.32 0.7492
0.449 POOLED 26.80 2218 −0.1687 0.13 −1.26 0.2078
PRL rs4712652 A 0.453 PIZARRA 5.28 828 0.203 0.23 0.87 0.3846
G 0.487 HORTEGA 5.69 1326 0.0367 0.15 0.24 0.8056
A 0.489 POOLED 5.91 2175 −0.115 0.13 −0.84 0.3976
PTER rs10508503 T 0.093 PIZARRA 5.10 841 −0.119 0.39 −0.30 0.7617
0.112 HORTEGA 5.27 1315 −0.279 0.23 −1.21 0.2238
0.105 POOLED 5.34 2174 −0.3695 0.21 −1.71 0.0866
BDNF rs925946 T 0.282 PIZARRA 10.40 848 0.128 0.24 0.51 0.6046
0.266 HORTEGA 17.97 1348 −0.071 0.16 −0.44 0.6578
0.272 POOLED 22.37 2215 0.0795 0.14 0.54 0.5855
rs10501087 C 0.253 PIZARRA 10.01 845 0.033 0.26 0.12 0.8988
0.231 HORTEGA 16.77 1348 0.0875 0.17 0.49 0.6231
0.240 POOLED 20.96 2214 0.1472 0.15 0.93 0.3493
FAIM2 rs7138803 A 0.352 PIZARRA 7.38 844 0.155 0.24 0.65 0.5159
0.352 HORTEGA 10.92 1348 −0.0643 0.15 −0.42 0.675
0.351 POOLED 12.81 2214 0.0513 0.14 0.36 0.7129
MAF rs1424233 A 0.483 PIZARRA 5.29 846 −0.192 0.23 −0.83 0.4074
G 0.499 HORTEGA 5.70 1348 0.2336 0.14 1.57 0.1158
A 0.495 POOLED 5.92 2216 −0.2422 0.13 −1.79 0.0725
NPC1 rs1805081 G 0.329 PIZARRA 5.25 845 −0.014 0.24 −0.05 0.9553
0.352 HORTEGA 5.64 1345 0.0046 0.15 0.03 0.9758
0.344 POOLED 5.83 2212 −0.0463 0.14 −0.32 0.7432
KCTD15 rs11084753 A 0.395 PIZARRA 5.62 846 0.093 0.23 0.39 0.6897
0.352 HORTEGA 6.44 1343 −0.1562 0.15 −1.01 0.31
0.367 POOLED 6.94 2210 0.0573 0.13 0.41 0.6781
CTNNBL1 rs6013029 T 0.091 PIZARRA 5.79 847 0.014 0.39 0.036 0.9708
0.066 HORTEGA 6.44 1348 −0.1522 0.30 −0.50 0.6133
0.076 POOLED 7.16 2216 0.1139 0.25 0.44 0.6547
A1: minor allele, *Number of non-missing individuals included in the analysis (top) and frequency of the haplotype in the sample (bottom); **t statistic coefficient;
p-values are not corrected for multiple testing; Bold type indicates significant association after Bonferroni correction. **The SNPs, rs4788102 in the SH2B1 and
rs4074134 of the BDNFOS genes are not included because are in high LD with the SNPs, rs8049439 of the ATXN2L gene (r2 0.94) and rs10501087of the BDNF
gene (r2 0.95), respectively.
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in the meta-analysis, rs9939609 of FTO (in the fixed
effect model), rs3101336 of the NEGR1 gene (both
fixed and random effects models) and rs3813929 of
the HTR2C gene (both fixed and random effects models).
The results for the meta-analysis and the statistical
heterogeneity are shown in Table 4.
Weighted genetic risk score
A genetic risk score was constructed with the risk alleles
of the six tagSNPs with a positive Beta in Hortega,
Pizarra and the Pooled analysis, that is: rs9939609 and
rs6499640 of the FTO gene; rs17782313 of the MC4R
gene; rs10838738 of the MTCH2 gene; rs7647305 of the
ETV5 gene; and rs10501087 of the BDNF gene.
The score constructed with the sum of the weighed risk
alleles was positively correlated with BMI in Pizarra and in
the pooled sample (r = 0.15 in Pizarra, p-value < 0.001;
r = 0.082 in the pooled sample, p-value < 0.001). FromTable 4 Meta-analysis for the association of BMI with individu
statistical heterogeneity for each SNP
CHR Gene SNP A1 P




18 MC4R rs17782313 C 0.1092
11 MTCH2 rs10838738 G 0.1222
1 NEGR1 rs3101336 A 0.0154
16 ATXN2L rs8049439 C 0.1431
23 HTR2C rs3813929 T 0.02603
5 ADRB2 rs12654778 A 0.8699
1 SEC16B rs10913469 C 0.9855
2 TMEM18 rs4854344 G 0.1106
INSIG2 rs7566605 C 0.9423
3 ADIPOQ rs17300539 A 0.758
rs3774261 A 0.6931
ETV5 rs7647305 T 0.2549
4 GNPDA2 rs10938397 G 0.2632
10 PTER rs10508503 T 0.2284
11 BDNF rs925946 T 0.9293
rs10501087 C 0.633
12 FAIM2 rs7138803 A 0.9989
18 NPC1 rs1805081 G 0.9971
19 KCTD15 rs11084753 A 0.5295
20 CTNNBL1 rs6013029 T 0.7034
CHR: Chromosome code; SNP: SNP identifier; A1: Minor allele code; P: Fixed-effects m
effects BETA estimate; BETA(R): Random-effects BETA estimate; Q: p-value for Cochrathe first to the fifth quintile of the score, the BMI
increases 2 Kg/m2 in Pizarra, 0.45 Kg/m2 in Hortega
and 0.93 Kg/m2 in the pooled analysis. The BMI values
for each quintile of the score as well as the regression
line between BMI and the risk score is shown in Figure 1.
However, the variance of BMI associated to individual
SNPs or to the score was very low (less than 1%). The
predictive value of the score for obesity was poor [area
under the curve (AUC) 0.515 and 0.594 in Hortega and
Pizarra respectively] (Additional file 5: Figure S3).
Discussion
The present study, carried out in two Spanish populations
with different characteristics, confirms the association
of BMI with some of the genes previously described
and provides further evidence of the influence of the
population characteristics on the association level. Variants
in the FTO gene were significantly associated with BMI
in one of the populations, Pizarra, whereas none of theal SNPs, for Pizarra and Hortega studies, and level of
BMI
P(R) Beta Beta(R) Q I
0.1902 0.3544 0.4843 0.0071 86.22
0.1921 −0.245 −0.3108 0.0788 67.64
0.6838 −0.0299 −0.1556 0.0076 85.97
0.1948 0.1659 0.1659 0.3853 0
0.1872 0.2563 0.2941 0.1879 42.34
0.1837 0.2031 0.2281 0.2157 34.75
0.04555 −0.3124 −0.2989 0.2647 19.6
0.5759 0.1893 0.1295 0.0975 63.58
0.02603 −0.4272 −0.4272 0.9414 0
0.9013 −0.0208 0.0254 0.1347 55.32
0.8286 −0.0031 0.0586 0.149 51.97
0.1106 −0.2701 −0.2701 0.781 0
0.9423 0.0097 0.0097 0.652 0
0.758 0.0573 0.0573 0.6433 0
0.6931 −0.0494 −0.0494 0.9466 0
0.2549 0.1763 0.1763 0.5226 0
0.2853 −0.1393 −0.1474 0.2784 14.87
0.2284 −0.2387 −0.2387 0.7263 0
0.9293 −0.012 −0.012 0.4992 0
0.633 0.0701 0.0701 0.8626 0
0.9989 −0.0002 −0.0002 0.4393 0
0.9971 −0.0005 −0.0005 0.9492 0
0.5295 −0.0808 −0.0808 0.3724 0
0.7034 −0.0914 −0.0914 0.738 0
eta-analysis p-value; P(R): Random-effects meta-analysis p-value; BETA: Fixed-
ne’s Q statistic; I: I2heterogeneity index (0-100).
Figure 1 Combined impact of risk alleles on average BMI in the
pooled analysis. For each individual, the number of risk alleles
(0,1,2) per SNP was weighted for their effect sizes and re-scaled by
dividing by the average of the all the effect sizes. The weighted risk
alleles for the selected SNPs were summed for each individual, and
the overall individual sum was rounded to the nearest integer to
represent the individual’s risk allele score. Along the x axis, individuals
in each risk allele category are shown (grouped ≤2 and ≥6 at the
extremes), and the mean BMI (± s.e.m.) is plotted (y axis on right),
with the line representing the regression of the mean BMI values
across the risk allele scores. The histogram (y axis on left) represents the
number of individuals for each risk-score category.
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population or in the pooled analysis.
A large battery of previously described genes associated
with BMI and obesity were selected for the present
study. They included not only the best characterized
FTO gene but also others recently described for which
the association was not as strong or was less consistently
reproduced. Among them, FTO, MC4R, MTCH2 and
HTR2C are the main associated loci with BMI and
obesity. Among the new discovered loci, ATXN2L, NEGR1
and SH2B1 have also shown a relationship with obesity.
Virtually all the SNPs in LD in the intron 1 of FTO were
associated with BMI in Pizarra population. Furthermore,
another SNP of FTO, rs6499640, not in LD with the others
was also associated with BMI when it was included in
the haplotypes. The estimated effect of the minor
allele of these SNPs was very low in concordance with
published studies in which carriers of the minor allele
of rs9939609 weighed about three kg more than carriers
of the other allele [4]. In the Pizarra population, the
strongest association was with rs9939609 although the
majority of polymorphisms in high LD with it reached
the significance even after adjusting by confounding
factors and by multiple comparisons. In the meta-analysis
performed by Willer et al [7], the estimated effect for these
variants ranged from 0.06 to 0.33 kg/m2, what means a
change in weight between 173-954 g per allele for adults
who are 1.60-1.80 m height [7]. The estimated maximum
effect of FTO gene alleles was higher in Pizarra populationas compare to the results of the meta-analysis although
in the pooled analysis the overall effect was similar.
In contrast with the strong association of FTO in the
Pizarra population, there was a weak association in
Hortega population. This difference could be attributed
to the characteristics of the two populations. The Pizarra
population was younger and had significantly higher mean
BMI and prevalence of obesity than Hortega population.
In fact, it has been suggested that the contribution of
FTO may be more evident in very obese and younger
populations [19]. There is also a trend toward less asso-
ciation with increase in age in some studies [4,20].
As a consequence of the low estimated effect of the
variants, none of the other loci out of FTO reached
the statistical significance after multiple comparisons
adjustments. However, some of them which were close
to the nominal p-value merit some comments. After
FTO, the most associated SNP with BMI in Pizarra
population was the rs17782313 of MC4R which it is in
agreement with previous meta-analysis [7,21]. Located
188 kb downstream of the MC4R, it was first identified
using GWAS in 16876 individuals of European descent
and replicated in 60352 adults. MC4R is a strong can-
didate gene for obesity because functional mutations
of this gene are associated with monogenic forms of
obesity [22]. The reported effect associated with this
variant was lower than the effect reported for the FTO
variants. The power to detect a true association decreases
when the associated effect of that variant decrease.
The integration of the information of relevant SNPs
into a genetic risk score might be a way to select those
subjects at high risk to develop obesity in the future. By
using the information provided in the present study, a
weighted genetic risk score (wGRS) was constructed by
using those Tag-SNPs with a positive Beta in Hortega,
Pizarra and the pooled analysis. This wGRS include
the following SNPs: rs9939609 and rs6499640 of the
FTO gene; rs17782313 of the MC4R gene; rs10838738
of the MTCH2 gene; rs7647305 of the ETV5 gene; and
rs10501087 of the BDNF gene.
From the first to the fifth quintile of the score, the
BMI increased 0.45 kg/m2 in Hortega, 2.00 kg/m2 in
Pizarra and 0.94 kg/m2 in the pooled analysis. These
data are in agreement to those obtained by the Genetic
Investigation of Anthropometric Traits (GIANT) project
in which subjects with the highest score weighed on
average 1.46 kg/m2 more than those with the lowest
score [7].
Despite the significant differences observed in BMI
and in the prevalence of obesity according to the score
categories, the explained variance for BMI was less than
1%, similar to the one predicted in a previous study for
Willer and colleagues [7]. Several potential explanations
can be offered for the low predictive value of the wGRS
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the tested variants and the skewed distribution of the
effect sizes [23]. Other potential explanations for the
low predictive value of the wGRS could be related with
the gene-gene or especially with the gene-environment
interactions which were not considered in the present
study [23]. Because the majority of these genes are
expressed in the central nervous system, acting in
appetite regulation, behaviour and basal energy expend-
iture [7,24-26], the importance of environmental factors,
mainly high energy intake and low physical activity,
should be considered. Estimation of energy intake and
physical activity, however, are unreliable because of
under- or over-reported [27]. Since the effect of these
genetic variants might be due to an increase of energy
intake [28], inclusion of energy intake could lead to a
marked improvement in prediction. This could have
clinical impact if we are able to identify those individ-
uals in which energy restriction below some threshold
should be strongly recommended.
The main limitation of the present study is that our
sample size was too small to detect association for the
majority of the tested variants with low estimated
effect, although we pooled two different populations to
overcome this problem. This may have influenced the
strength of the association but not the size of the effect,
which was similar to that reported in one meta-analysis
[7]. The appropriateness of combining these two popu-
lations in one is somehow controversial and merits
some comments. Both samples share similar genetic
backgrounds due to the low immigration rate and are
supposed to be homogeneous ethnic populations. Because
of this, we did not expect population stratification in our
samples what can favour the pooled strategy. However,
they belong to different geographical regions of Spain
and they have completely different clinical characteristics.
This clinical heterogeneity probably has had a great
influence in the pooled analysis results. For this reason
we also decided to perform a meta-analysis to assess
the statistical heterogeneity. For some of the SNPs such as
those of the FTO gene, the level of statistical heterogeneity
based on the p-value for Cochrane’s Q statistic and the I2
heterogeneity index, was very high. For other SNPs,
such as the rs12654778 at ADRB2 with a priori adequate
statistical power to detect significant association, we did
not find any. The clinical heterogeneity and the level of
statistical heterogeneity, at least moderate, can justify the
lack of association. Besides we cannot be sure for certain
that the prior statistical power for that SNP is that high
due to the previously commented considerations.
The different lipid and carbohydrate metabolic profiles
observed between populations may be related with the
different characteristics of the target populations with
markedly different lifestyles. Several studies have shownthat the effects of FTO alleles are attenuated by exercise
[29,30]. Individuals from Pizarra population belonged to
a rural area and were significantly younger than those
from the Hortega study. The individuals from the latter
study were recruited in the area covered by a tertiary
hospital and the majority of them lived in urban areas. This
population was also even regarding to gender distribution
as compare with Pizarra population, which included
mostly females. Because of the potential influence of
the population to which each individual belongs, we
also adjusted the analysis by this factor, and the results
remained unchanged.Conclusions
In conclusion, baseline characteristics of the populations,
mainly age and grade of obesity, have a strong influence
in the genetic association results. FTO was the only
locus that was clearly associated with BMI in this study.
None of the other loci including the MC4R, MTCH2 or
the newly discovered ones, such as ATXN2L, NEGR1
and SH2B1 were associated with BMI in this study. The
risk associated with these polymorphisms is low and
the overall effect in BMI is minimal. Considering the
high heritability of obesity, new variants remain to be
discovered. As commented previously, the majority of
the analysed loci are related to central nervous system
mechanisms of obesity but many other mechanisms
can influence body weight and their contribution have
not been elucidated yet. New strategies, like the study
of lean individuals [31-34], translational information
from animal models [35-38], nutrigenomics [39,40], as
well as the interaction with energy intake and physical
activity may lead to a better understanding of the genetic
component in the physiopathology of obesity.Additional files
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